The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of NASDAQ? listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Inception Date: 05/02/2001
Primary Benchmark: NASDAQ Biotechnology TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.47%
Management Expense Ratio: 0.47 %
|BIIB||Biogen Inc.||8.55 %|
|GILD||Gilead Sciences Inc.||7.99 %|
|AMGN||Amgen Inc.||7.91 %|
|CELG||Celgene Corporation||7.89 %|
|ILMN||Illumina Inc.||6.01 %|
|REGN||Regeneron Pharmaceuticals Inc.||4.82 %|
|VRTX||Vertex Pharmaceuticals Incorporated||4.26 %|
|ALXN||Alexion Pharmaceuticals Inc.||3.21 %|
|MYL||Mylan N.V.||2.38 %|
|BMRN||BioMarin Pharmaceutical Inc.||2.08 %|
|PSCH||Invesco S&P SmallCap Health Ca..||0.29 %||
|BBH||VanEck Vectors Biotech ETF||0.35 %||
|PTH||Invesco DWA Healthcare Momentu..||0.60 %||
|PPH||VanEck Vectors Pharmaceutical ..||0.35 %||
|CNCR||Loncar Cancer Immunotherapy ET..||0.79 %||
|BTEC||Principal Healthcare Innovator..||0.42 %||
|FTXH||First Trust Nasdaq Pharmaceuti..||0.60 %||
|GNRX||Market Vectors Generic Drugs E..||0.57 %||
|SLIM||The Obesity ETF||0.50 %||
|LNGR||Global X Longevity Thematic ET..||0.52 %||
|Market Performance vs.
|Market Performance vs. Exchange (NASDAQ Global Market)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||22.86%||18%||F||58%||F|
|Risk Adjusted Return||49.50%||36%||F||57%||F|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company has under performed its peers on annual average total returns in the past 5 years.